Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 794 across all filing types
Latest filing 2020-09-07 Regulatory Filings
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a communication addressed to stock exchanges and depositories regarding the details of shares dematerialized during August 2020. It references Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, and includes a certificate from the company's Registrar and Transfer Agent (RTA) confirming the dematerialized shares as of August 31, 2020. The content is an official notification about share dematerialization status rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is 3857 characters, which is relatively short and primarily informational. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2020-09-07 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains unaudited financial results for the quarter ended June 30, 2020, including detailed financial figures such as total income, net profit, earnings per share, and reserves. It references compliance under SEBI Listing Obligations and Disclosure Requirements, which is typical for quarterly financial disclosures. The presence of detailed financial data and analysis for a quarter indicates this is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2020-09-05 English
Financial Result Updates
Regulatory Filings
2020-09-03 English
Outcome of Board Meeting
Regulatory Filings
2020-09-03 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-09-01 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-08-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.